COMPASS Pathways

We collaborate with leading scientific and political institutions worldwide to design and develop ground-breaking research and global policy initiatives. Through the Scientific Programme – led by Amanda – we collaborate with leading experts and institutions to design, initiate, and direct scientific research projects, including clinical trials. The studies focus on cannabis, MDMA, and psychedelics (LSD, psilocybin, DMT, 5-MeO-DMT), and explore how these substances act upon the human brain, using the latest developments in neuroscience and brain imaging technology.

We built out the team with clinical, psychiatric and psychedelic specialists who are able to support our clients’ trial design and delivery. The UK is becoming a hub for market leading psychedelic companies, from Compass Pathways to Small Pharma and Beckley Psytech, the largest companies and the most highly anticipated drug candidates are being discovered by British drug developers. We opened Europe’s first commercial research site dedicated to psychedelic trials, grew our team and signed additional clients. Set & Setting: Increased focus on the broader components of psychedelic-assisted therapies, from music and therapy modality to supporting technology and environment. Growing debate: Critical focus on the quality and ethics of trials, access to psychedelic treatment and IP in psychedelic therapies and drug development. Our purpose-built clinic is Europe’s first commercial research site specialising in psychedelics and advanced technologies.

Our goal is to transform the lives of patients with improved therapeutic options. We are focused on designing innovative trials with clinical endpoints directly related to patient benefit, and we seek to recruit patients who will benefit from treatment with our product candidates. Our skills in clinical development define our core expertise in central nervous system disorders.

We are a biopharmaceutical company that leverages a decentralized platform approach to incubate and accelerate the development of highly effective mental health treatments that address the unmet needs of patients. We are committed to acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in the mental health space. Depression is one of the most prevalent psychiatric disorders and a leading cause of disability worldwide, affecting an estimated 300 million people globally. Equipped with a diverse and dedicated team, we are making a concerted effort to redefine mental health paradigms. To minimize development risk, we focus on compounds that have previously been used in humans and have established safety profiles. Our unique model combines funding with operational expertise to develop innovative and impactful CNS therapeutics. The Phase 1b trial of VLS-01 investigates the pharmacokinetics, pharmacodynamics, safety and tolerability of atai’s proprietary, optimized oral transmucosal formulation…. Strategic investment in Beckley Psytech reinforces atai’s position as the biopharmaceutical company with the largest and most diverse portfolio of….

Our goal is to discover and develop novel, first-in-class medicines for patients suffering from 1) the most aggressive forms of cancer with currently limited treatment options, and 2) psychiatric disorders that are poorly addressed by current medications, including addiction and treatment resistant depression. Our innovative technology platform allows for exploiting inadequately served targets that require a highly adaptive and specialized approach to drug discovery.

At GH Research, we focus on achieving the highest level of quality in our work, coupled with fresh thinking and an entrepreneurial spirit. GH Research was founded in 2018, and since then, two of our novel and proprietary mebufotenin (5-methoxy-N,N-dimethyltryptamine, 5-MeO-DMT) product candidates have entered clinical development; our lead product candidate, GH001, is currently being investigated in a randomized, double-blind, placebo-controlled Phase 2b trial in patients with TRD, and in two open-label Phase 2a proof-of-concept trials in patients with bipolar II disorder with a depressive episode (BDII) and patients with postpartum depression (PPD). Foundation of GH Research and technical development work of drug product. GH Research Reports Full Year 2023 Financial Results and Provides Business Updates. GH Research is a clinical-stage pharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. With its novel and proprietary mebufotenin (5-methoxy-N,N-dimethyltryptamine, 5-MeO-DMT) products and current clinical development programs in treatment-resistant depression (TRD), bipolar II disorder with a depressive episode (BDII) and postpartum depression (PPD), GH Research is aiming to provide improved treatments for difficult-to-treat depression with increased remission rates, faster onset of action, durable effects, and improved tolerability and convenience. Remission at day 7 of the trial was achieved in 25% to 50% when using a single dose of GH001 and in 87.5% of patients when using an individualized dosing regimen (IDR) of GH001. GH Research is currently developing three mebufotenin-based product candidates, with GH001, a pulmonary inhalation formulation of mebufotenin, and its development in TRD, being the lead program.